The Black Book of Psychotropic Dosing and Monitoring
Psychopharmacology Bulletin August 12, 2025 Alan F. Schatzberg, D Charles 15 citations
Several innovative psychiatric drugs have recently been approved or are nearing approval. Auvelity (bupropion/dextromethorphan) speeds antidepressant response and remission more than bupropion alone. Zuranolone, a 14-day oral treatment for postpartum depression, improves symptoms at day 15 and through day 45. Gepirone, a 5HT1a partial agonist, was approved for major depression based on positive trials and a favorable side effect profile. Cariprazine was approved as an adjunctive treatment for resistant major depression at 1.5 mg daily. MDMA-assisted psychotherapy for PTSD led to over 70% of subjects no longer meeting PTSD criteria, compared to 46% with psychotherapy and placebo. Xenomeline/tropsium (KarXT), a muscarinic M1M4 agonist, effectively treats positive and negative schizophrenia symptoms without dopamine antagonism. Lecanemab, a monoclonal antibody targeting beta-amyloid, slowed cognitive decline by 27% in early Alzheimer's disease.